Allarity Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

ALLR$0.91-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except for share and per share data)

	2025	2024
Revenue:
License Revenue	$320	$—
Total Revenue	320	—
Operating expenses:
Research and development	6,601	6,096
Impairment of intangible assets	—	9,703
General and administrative	6,324	11,442
Total operating expenses	12,925	27,241
Loss from operations	(12,605)	(27,241)
Other income (expense)
Interest income	801	533
Interest expenses	(185)	(653)
Foreign exchange gains (losses)	757	(212)
Change in fair value adjustment of warrant derivative liabilities	1	2,677
Total other income	1,374	2,345
Loss before income tax expense (benefit)	(11,231)	(24,896)
Income tax expense (benefit)	—	(381)
Net loss	(11,231)	(24,515)
Deemed dividends on Series A Preferred Stock	—	(299)
Deemed dividend on Series A Convertible Redeemable Preferred Stock	—	(562)
Gain on extinguishment of Series A Preferred Stock	—	222
Net loss attributable to common stockholders	$(11,231)	$(25,154)
Net loss per common share, basic and diluted	$(0.78)	$(15.65)
Weighted average common shares outstanding, basic and diluted	14,378,942	1,606,989
Other comprehensive loss
Net loss	$(11,231)	$(24,515)
Change in cumulative translation adjustment	(667)	57
Total comprehensive loss	$(11,898)	$(24,458)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.